First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study by Giandomenico Roviello, Javier Molina-Cerrillo, Francesco Massari, Linda Cerbone, Ondrej Fiala, Giuseppe Fornarini, Fernando Sabino Marques Monteiro, Carlo Cattrini, Johannes Landmesser, Carlo Messina, Anca Zgura, Sara Elena Rebuzzi, Andrey Soares, Francesco Carrozza, Jawaher Ansari, Francesco Grillone, Zsófia Küronya, Lorena Incorvaia, Dipen Bhuva, Cinzia Ortega, Cecilia Nasso, Ravindran Kanesvaran, Ilaria Zampiva, Camillo Porta, Sebastiano Buti, Matteo Santoni

Get full text

Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1) by Matteo Santoni, Giandomenico Roviello, Enrique Grande, Ugo De Giorgi, Ondrej Fiala, Emmanuel Seront, Javier Molina-Cerrillo, Renate Pichler, Zin W. Myint, Jakub Kucharz, Ravindran Kanesvaran, Thomas Büttner, Martin Pichler, Umberto Basso, Jindrich Kopecky, Maria T. Bourlon, Linda Cerbone, Tomas Buchler, Alvaro Pinto, Alfonso Gómez de Liaño, Caterina Gianni, Anca Zgura, Pasquale Rescigno, Jawaher Ansari, Orazio Caffo, Zsófia Küronya, Maria Giuseppa Vitale, Dipen Bhuva, Martina Catalano, Nuno Vau, Ray Manneh Kopp, Sebastiano Buti, Aristotelis Bamias, Camillo Porta, Kaisa Sunela, Francesco Massari

Get full text